Bortezomib protects from varicose-like venous remodeling

FASEB Journal

Volumn 28, Issue 8, 2014, Pages 3518-3527

  Pfisterer, Larissa ^a   Meyer, Ralph ^a   Feldner, Anja ^a   Drews, Oliver ^a   Hecker, Markus ^a   Korff, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Myocardin; Proteasome; Varicose veins; Venous smooth muscle cell phenotype

Indexed keywords

BORTEZOMIB; COLLAGEN GEL; MYOCARDIN; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; SMOOTH MUSCLE FIBER; TOPICAL TREATMENT; VARICOSIS; VENOUS SMOOTH MUSCLE CELL;

MYOCARDIN; PROTEASOME; VARICOSE VEINS; VENOUS SMOOTH MUSCLE CELL PHENOTYPE;

ANIMALS; ANIMALS, OUTBRED STRAINS; BORONIC ACIDS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PYRAZINES; SPHEROIDS, CELLULAR; TRANS-ACTIVATORS; VARICOSE VEINS;

EID: 84905223577     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-250464     Document Type: Article

References (37)

1. Beebe-Dimmer, J. L., Pfeifer, J. R., Engle, J. S., and Schottenfeld, D. (2005) The epidemiology of chronic venous insufficiency and varicose veins. Ann. Epidemiol. 15, 175-184 (Pubitemid 40269465)
2. Clark, A., Harvey, I., and Fowkes, F. G. (2010) Epidemiology and risk factors for varicose veins among older people: cross-sectional population study in the UK. Phlebology 25, 236-240
3. Iannuzzi, A., Panico, S., Ciardullo, A. V., Bellati, C., Cioffi, V., Iannuzzo, G., Celentano, E., Berrino, F., and Rubba, P. (2002) Varicose veins of the lower limbs and venous capacitance in postmenopausal women: relationship with obesity. J. Vasc. Surg. 36, 965-968 (Pubitemid 35316070)
4. Burkitt, D. P., Townsend, A. J., Patel, K., and Skaug, K. (1976) Varicose veins in developing countries. Lancet 2, 202-203
5. Lee, A. J., Evans, C. J., Allan, P. L., Ruckley, C. V., and Fowkes, F. G. (2003) Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J. Clin. Epidemiol. 56, 171-179 (Pubitemid 36315944)
6. Eberhardt, R. T., and Raffetto, J. D. (2005) Chronic venous insufficiency. Circulation 111, 2398-2409 (Pubitemid 40647076)
7. Atta, H. M. (2012) Varicose veins: role of mechanotransduction of venous hypertension. Int. J. Vasc. Med. 2012:538627
8. Feldner, A., Otto, H., Rewerk, S., Hecker, M., and Korff, T. (2011) Experimental hypertension triggers varicosis-like maladaptive venous remodeling through activator protein-1. FASEB J. 25, 3613-3621
9. Tang, R. H., Zheng, X. L., Callis, T. E., Stansfield, W. E., He, J., Baldwin, A. S., Wang, D. Z., and Selzman, C. H. (2008) Myocardin inhibits cellular proliferation by inhibiting NF-κB(p65)-dependent cell cycle progression. Proc. Natl. Acad. Sci. U. S. A. 105, 3362-3367 (Pubitemid 351723558)
10. Wang, Z., Wang, D. Z., Hockemeyer, D., McAnally, J., Nordheim, A., and Olson, E. N. (2004) Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 428, 185-189 (Pubitemid 38374315)
11. Long, X., Bell, R. D., Gerthoffer, W. T., Zlokovic, B. V., and Miano, J. M. (2008) Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler. Thromb. Vasc. Biol. 28, 1505-1510
12. Huang, J., Cheng, L., Li, J., Chen, M., Zhou, D., Lu, M. M., Proweller, A., Epstein, J. A., and Parmacek, M. S. (2008) Myocardin regulates expression of contractile genes in smooth muscle cells and is required for closure of the ductus arteriosus in mice. J. Clin. Invest. 118, 515-525 (Pubitemid 351206542)
13. Pfisterer, L., Feldner, A., Hecker, M., and Korff, T. (2012) Hypertension impairs myocardin function: a novel mechanism facilitating arterial remodelling. Cardiovasc. Res. 96, 120-129
14. Glickman, M. H., and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428 (Pubitemid 34654457)
15. Goldberg, A. L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899
16. Xie, P., Fan, Y., Zhang, H., Zhang, Y., She, M., Gu, D., Patterson, C., and Li, H. (2009) CHIP represses myocardin-induced smooth muscle cell differentiation via ubiquitin-mediated proteasomal degradation. Mol. Cell. Biol. 29, 2398-2408
17. Drews, O., Tsukamoto, O., Liem, D., Streicher, J., Wang, Y., and Ping, P. (2010) Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ. Res. 107, 1094-1101
18. Gomes, A. V., Zong, C., and Ping, P. (2006) Protein degradation by the 26S proteasome system in the normal and stressed myocardium. Antioxid. Redox Signal. 8, 1677-1691 (Pubitemid 44726341)
19. Powell, S. R. (2006) The ubiquitin-proteasome system in cardiac physiology and pathology. Am. J. Physiol. Heart Circ. Physiol. 291, H1-H19
20. Tung, D., Cheung, P. H., Kaur, P., Foreman, O., Kavirayani, A., Hain, H. S., and Saha, S. (2011) Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology 88, 100-113
21. Korff, T., Kimmina, S., Martiny-Baron, G., and Augustin, H. G. (2001) Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J. 15, 447-457 (Pubitemid 32141436)
22. Pfisterer, L., Feldner, A., Hecker, M., and Korff, T. (2012) Hypertension impairs myocardin function-a novel mechanism facilitating arterial remodeling. Cardiovasc Res 96, 120-129
23. Li, S., Wang, X., Li, Y., Kost, C. K., Jr., and Martin, D. S. (2013) Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats. PLoS One 8, e78564
24. Lim, C. S., and Davies, A. H. (2009) Pathogenesis of primary varicose veins. Br. J. Surg. 96, 1231-1242
25. Somers, P., and Knaapen, M. (2006) The histopathology of varicose vein disease. Angiology 57, 546-555 (Pubitemid 44564310)
26. Wali, M. A., and Eid, R. A. (2002) Changes of elastic and collagen fibers in varicose veins. Int. Angiol. 21, 337-343 (Pubitemid 36322371)
27. Parmacek, M. S. (2007) Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ. Res. 100, 633-644
28. Yoshida, T., Kawai-Kowase, K., and Owens, G. K. (2004) Forced expression of myocardin is not sufficient for induction of smooth muscle differentiation in multipotential embryonic cells. Arterioscler. Thromb. Vasc. Biol. 24, 1596-1601 (Pubitemid 39180881)
29. Scott, T. E., LaMorte, W. W., Gorin, D. R., and Menzoian, J. O. (1995) Risk factors for chronic venous insufficiency: a dual case-control study. J. Vasc. Surg. 22, 622-628
30. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (Pubitemid 36741588)
31. Weathington, N. M., Sznajder, J. I., and Mallampalli, R. K. (2013) The emerging role of the ubiquitin proteasome in pulmonary biology and disease. Am. J. Respir. Crit. Care Med. 188, 530-537
32. Pagan, J., Seto, T., Pagano, M., and Cittadini, A. (2013) Role of the ubiquitin proteasome system in the heart. Circ. Res. 112, 1046-1058
33. Tydlacka, S., Wang, C. E., Wang, X., Li, S., and Li, X. J. (2008) Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J. Neurosci. 28, 13285-13295
34. Barringhaus, K. G., and Matsumura, M. E. (2007) The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury. Exp. Clin. Cardiol. 12, 119-124 (Pubitemid 47526936)
35. Herrmann, J., Saguner, A. M., Versari, D., Peterson, T. E., Chade, A., Olson, M., Lerman, L. O., and Lerman, A. (2007) Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ. Res. 101, 865-874 (Pubitemid 350287173)
36. Wilck, N., Fechner, M., Dreger, H., Hewing, B., Arias, A., Meiners, S., Baumann, G., Stangl, V., Stangl, K., and Ludwig, A. (2012) Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arterioscler. Thromb. Vasc. Biol. 32, 1418-1426
37. Bunn, P. A., Jr. (2004) The potential role of proteasome inhibitors in the treatment of lung cancer. Clin. Cancer Res. 10, 4263s-4265s